Dexcom Inc.

Dexcom earns money from a recurring purchase: a disposable sensor component that must be replaced on a regular cycle, sold alongside longer-lived reusable hardware. Prices are set through contracts with distributors and third-party payors rather than posted retail prices, and are reduced by rebates, chargebacks and returns. Net income has been positive in every year of its recent financial history.

CompanyGraph's assigned framework for this industry centers scaling on clearing a regulatory approval gate. What is actually on file describes a different mechanism: revenue scales mainly by adding patients to an installed base that then keeps buying a consumable component on a recurring basis, closer to a repeat-purchase pattern than a pipeline-approval one. Because the product is physical, meeting new demand still requires building and licensing additional manufacturing capacity rather than simply adding software capacity, so growth stays tied to physical and regulatory build-out even though the revenue mechanism itself is a repeat-purchase one. Returns on the assets already deployed read as elevated relative to industry peers across several efficiency measures at once, not just through financial leverage.

Dexcom's own filings describe dependence on a small number of suppliers, including sole sources for a key integrated circuit and for certain polymers used in its sensor membranes, plus a limited number of sources for other customized components. It manufactures most of what it sells itself, at a small number of its own sites, rather than through contract manufacturers, which concentrates that step of production. It also depends on distributors and payors: on distributors and wholesalers to reach some patients, and on government and private insurers choosing to reimburse its products before many patients can afford to keep buying them.

Individual patients are Dexcom's direct customers, drawn from a broad base worldwide, and most of what they pay is actually reimbursed by government programs and private insurers rather than paid out of pocket, so those payors' coverage decisions sit between Dexcom and the money it collects. Outside the United States, its counterparties are mostly government bodies rather than individual buyers. Its data also feeds into partner insulin pumps and pens that act on its readings, so those connected devices depend on the glucose data stream it produces, and caregivers and clinicians who receive shared readings depend on that same stream.

In CompanyGraph's broader mapping across industries, the particular combination of physically producing a regulated product under an approval-gated model is uncommon, shared with only a handful of other companies it tracks, including AP Biosciences, CHA Biotech and Niagen Bioscience. Dexcom itself names Abbott, Medtronic, Roche, LifeScan and Ascensia as its direct competitors in glucose monitoring, and points to sensor accuracy, connectivity, integration with insulin-delivery devices, distribution reach, brand acceptance and regulatory experience as what it competes on, its own account of its position rather than something CompanyGraph has independently verified. Neither of these shows that rivals are structurally unable to copy what it does.

Dexcom's own account of what limits its growth centers on physical and regulatory capacity rather than a single approval decision: it names insufficient manufacturing capacity, the need for regulatory and facility licensing, equipment and automation design, materials procurement, production yields and quality control as constraints, alongside the difficulty of hiring and keeping experienced manufacturing, quality and technical staff. It also names limits on coverage and reimbursement from insurers as a separate constraint on adoption. The industry-level framework this is tested against centers scale on a regulatory approval gate; here the company's own account puts more weight on manufacturing capacity and reimbursement than on a single clearance event, so the general pattern bends rather than simply holding.

In its own risk disclosures, Dexcom lists first: prices falling without matching cost reductions, insufficient coverage or reimbursement from payors, research and development that fails to produce results, loss of market acceptance, regulatory noncompliance including the warning letter it has received, and insufficient manufacturing capacity. It also names dependence on single or limited-source suppliers, outsourced services, and concentrated distribution arrangements as risks in the same filing. This is the company's own account of what could hurt it, not a conclusion CompanyGraph has drawn independently.

Dexcom operates under oversight from FDA in the United States and equivalent medical-device regulators in the other markets where it sells, any of which can restrict what it is allowed to sell or how it must be manufactured. It has disclosed a warning letter from FDA over manufacturing and quality-system compliance, and separately discloses pending securities litigation. It also names exposure to import and export licensing rules, tariffs and trade measures, sanctions rules, and currency movements, since it sells in many currencies while much of its cost base sits in one.